Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Investigating the gut microbiome in relation to metabolic and cognitive dysfunction in first episode psychosis patients
FY 2018-19
Summary
Antipsychotics (AP)s are the cornerstone of treatment for many severe mental illnesses. They are increasingly used on-and off-label, but are associated with significant metabolic side-effects. In addition to the cardiometabolic implications of these adverse-effects, obesity and insulin resistance have been shown to adversely impact brain structure and cognition. Patients who are most vulnerable to these metabolic adverse effects are first episode psychosis (FEP) patients. Recent evidence suggests the gut microbiome (GMB) may assist in explaining the cognitive functioning and metabolic risk in FEP patients and their AP response.
The study hypotheses are: 1) FEP patients will have greater GMB diversity and fewer Bacteroidetes than healthy controls (HCs); 2) AP-treatment will change the GMB of FEP patients; 3) changes will correlate with metabolic side-effects; 4) GMB composition and diversity will differ between patients who do and do not develop metabolic abnormalities, and 5) change in the GMB towards a dysmetabolic profile will be associated with worse cognitive outcomes.
FEP patients (n= 25) and HCs (n=25) will be matched for demographics, BMI, and socioeconomic status. At baseline, participants will undergo a detailed medical history, anthropometric measures, standard cognitive and psychopathology assessments, fasting blood assessments, and fecal sample collection. These procedures will be repeated at mid and endpoint.
To our knowledge, this study is the first investigation of GMB and AP-induced metabolic side effects in FEP patients. This study has the potential to unravel the role of GMB in the high metabolic comorbidity observed in FEP patients, in relation to treatment response and cognition, thereby leading to novel intervention strategies.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
406549
Name
Costa-Dookhan Kenya A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating the gut microbiome in relation to metabolic and cognitive dysfunction in first episode psychosis patients
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Antipsychotics; Cognition; Diabetes; First Episode Psychosis; Gut Microbiome; Interaction; Metabolism; Obesity; Schizophrenia
Abstract
Antipsychotics (AP)s are the cornerstone of treatment for many severe mental illnesses. They are increasingly used on-and off-label, but are associated with significant metabolic side-effects. In addition to the cardiometabolic implications of these adverse-effects, obesity and insulin resistance have been shown to adversely impact brain structure and cognition. Patients who are most vulnerable to these metabolic adverse effects are first episode psychosis (FEP) patients. Recent evidence suggests the gut microbiome (GMB) may assist in explaining the cognitive functioning and metabolic risk in FEP patients and their AP response.
The study hypotheses are: 1) FEP patients will have greater GMB diversity and fewer Bacteroidetes than healthy controls (HCs); 2) AP-treatment will change the GMB of FEP patients; 3) changes will correlate with metabolic side-effects; 4) GMB composition and diversity will differ between patients who do and do not develop metabolic abnormalities, and 5) change in the GMB towards a dysmetabolic profile will be associated with worse cognitive outcomes.
FEP patients (n= 25) and HCs (n=25) will be matched for demographics, BMI, and socioeconomic status. At baseline, participants will undergo a detailed medical history, anthropometric measures, standard cognitive and psychopathology assessments, fasting blood assessments, and fecal sample collection. These procedures will be repeated at mid and endpoint.
To our knowledge, this study is the first investigation of GMB and AP-induced metabolic side effects in FEP patients. This study has the potential to unravel the role of GMB in the high metabolic comorbidity observed in FEP patients, in relation to treatment response and cognition, thereby leading to novel intervention strategies.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Costa-Dookhan, Kenya A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~